Prosecution Insights
Last updated: April 19, 2026

Epitech Group S P A

4 pending office actions

Portfolio Summary

4
Total Pending OAs
2
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18303789 N-PALMITOYLETHANOLAMIDE AND MELATONIN FOR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER NEUROBEHAVIORAL DISORDERS SIMILARLY ACCOMPANIED BY RESTLESSNESS, IRRITABILITY, SLEEP DISORDERS, AND POTENTIALLY STEREOTYPIES TRAN, SUSAN T 1615 Final Rejection Apr 20, 2023
17949754 N-PALMITOYLETHANOLAMIDE AND DOCOSAHEXAENOIC ACID FOR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER DEPRESSIVE SYNDROMES ADLAM, CHANTAL PETA-GAYE 1622 Non-Final OA Sep 21, 2022
17836902 COMPOSITION OF N-PALMITOYL-ETHANOLAMIDE AND BAICALEIN IN CO-MICRONIZED FORM YOUNG, MICAH PAUL 1618 Final Rejection Jun 09, 2022
17691572 N-PALMITOYL-ETHANOLAMIDE FOR USE IN THE PREVENTION OF COLORECTAL CARCINOMA WORSHAM, JESSICA N 1615 Non-Final OA Mar 10, 2022

Managing Epitech Group S P A's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month